4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001209191-24-004397
Chief Financial Officer gave up 1,417 shares (to pay taxes)
- Chief Financial Officer acquired 4,975 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Balthaser Kevin Chief Financial Officer | 2024-03-01 | Option exercise | +1,100 | 21,525 | D | ||
| Balthaser Kevin Chief Financial Officer | 2024-03-01 | Shares withheld for taxes | −313 | $1.24 | $388 | 21,212 | D |
| Balthaser Kevin Chief Financial Officer | 2024-03-01 | Option exercise | +2,375 | 23,587 | D | ||
| Balthaser Kevin Chief Financial Officer | 2024-03-01 | Shares withheld for taxes | −677 | $1.24 | $839 | 22,910 | D |
| Balthaser Kevin Chief Financial Officer | 2024-03-02 | Option exercise | +1,500 | 24,410 | D | ||
| Balthaser Kevin Chief Financial Officer | 2024-03-02 | Shares withheld for taxes | −427 | $1.24 | $529 | 23,983 | D |
| Derivatives | |||||||
| Balthaser Kevin Chief Financial Officer | 2024-03-01 | Option exercise · Restricted Stock Units | −1,100 | 1,100 | D | ||
| Balthaser Kevin Chief Financial Officer | 2024-03-01 | Option exercise · Restricted Stock Units | −2,375 | 4,750 | D | ||
| Balthaser Kevin Chief Financial Officer | 2024-03-02 | Option exercise · Restricted Stock Units | −1,500 | 0 | D | ||
Loading xslF345X05/doc4.xml…